Surgery for brain metastases – real-world prognostic factors’ association with survival

References

• Davis FG, Dolecek TA, McCarthy BJ, et al. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012;14(9):1171–1177.
   PubMed Web of Science ®Google Scholar
• Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–54.
   PubMed Web of Science ®Google Scholar
• Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–1521.
   PubMed Web of Science ®Google Scholar
• Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19(2):162–174.
   PubMed Web of Science ®Google Scholar
• Nieder C, Spanne O, Mehta MP, et al. Presentation, patterns of care, and survival in patients with brain metastases. Cancer. 2011;117(11):2505–2512.
   PubMed Web of Science ®Google Scholar
• Wong J, Hird A, Kirou-Mauro A, et al. Quality of life in brain metastases radiation trials: a literature review. Curr Oncol. 2008;15(5):25–45.
   PubMed Web of Science ®Google Scholar
• Herman MA, Tremont-Lukats I, Meyers CA, et al. Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol. 2003;26(3):273–279.
   PubMed Web of Science ®Google Scholar
• Tsao MN. Brain metastases: advances over the decades. Ann Palliat Med. 2015;4(4):225–232.
   PubMed Web of Science ®Google Scholar
• Chao J-H, Phillips R, Nickson JJ. Roentgen-ray therapy of cerebral metastases. Cancer. 1954;7(4):682–689.
   PubMed Web of Science ®Google Scholar
• Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–1060.
   PubMed Web of Science ®Google Scholar
• Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–1044.
   PubMed Web of Science ®Google Scholar
• Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–409.
   PubMed Web of Science ®Google Scholar
• Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–2014.
   PubMed Web of Science ®Google Scholar
• Lazaro T, Brastianos PK. Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncol. 2017;6(2):139–151.
   PubMedGoogle Scholar
• Hendriks LEL, Bootsma G, Mourlanette J, et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur J Cancer. 2019;116:182–189.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–681.
   PubMed Web of Science ®Google Scholar
• Schapira E, Hubbeling H, Yeap BY, et al. Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys. 2018;101(3):624–629.
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.
   PubMed Web of Science ®Google Scholar
• Mut M. Surgical treatment of brain metastasis: a review. Clin Neurol Neurosurg. 2012;114(1):1–8.
   PubMed Web of Science ®Google Scholar
• Bhangoo SS, Congress of Neurologic Surgeons (CNS), Linskey ME, Kalkanis SN. Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am. 2011;22(1):97–104.
   PubMed Web of Science ®Google Scholar
• Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–751.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510–514.
   PubMed Web of Science ®Google Scholar
• Nieder C, Geinitz H, Molls M. Validation of the graded prognostic assessment index for surgically treated patients with brain metastases. Anticancer Res. 2008;28(5b):3015–3017.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–425.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38(32):3773–3784.
   Web of Science ®Google Scholar
• Sperduto PW, Deegan BJ, Li J, et al. Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool. Neuro Oncol. 2018;20(12):1652–1660.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Fang P, Li J, et al. Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clin Transl Radiat Oncol. 2019;18:39–45.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Jiang W, Brown PD, et al. Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (melanoma-molGPA). Int J Radiat Oncol Biol Phys. 2017;99(4):812–816.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Mesko S, Li J, et al. Beyond an updated Graded Prognostic Assessment (breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol Phys. 2020;107(2):334–343.
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol. 2017;3(6):827–831.
   PubMed Web of Science ®Google Scholar
• Pawloski PA, Brooks GA, Nielsen ME, et al. A systematic review of clinical decision support systems for clinical oncology practice. J Natl Compr Canc Netw. 2019;17(4):331–338.
   PubMed Web of Science ®Google Scholar
• Antoni D, Clavier JB, Pop M, et al. Institutional, retrospective analysis of 777 patients with brain metastases: treatment outcomes and diagnosis-specific prognostic factors. Int J Radiat Oncol Biol Phys. 2013;86(4):630–637.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Suh JH, Kotecha R, Chao ST, et al. Current approaches to the management of brain metastases. Nat Rev Clin Oncol. 2020;17(5):279–299.
   PubMed Web of Science ®Google Scholar
• Kavouridis VK, Harary M, Hulsbergen AFC, et al. Survival and prognostic factors in surgically treated brain metastases. J Neurooncol. 2019;143(2):359–367.
   PubMed Web of Science ®Google Scholar
• Liu Z, Lei B, Zheng M, et al. Prognostic factors in patients treated with surgery for brain metastases: A single-center retrospective analysis of 125 patients. Int J Surg. 2017;44:204–209.
   PubMed Web of Science ®Google Scholar
• Pojskic M, Bopp MHA, Schymalla M, et al. Retrospective study of 229 surgically treated patients with brain metastases: Prognostic factors, outcome and comparison of recursive partitioning analysis and diagnosis-specific graded prognostic assessment. Surg Neurol Int. 2017;8(1):259.
   PubMedGoogle Scholar
• Rogne SG, Ronning P, Helseth E, et al. Craniotomy for brain metastases: a consecutive series of 316 patients. Acta Neurol Scand. 2012;126(1):23–31.
   PubMed Web of Science ®Google Scholar
• Schackert G, Lindner C, Petschke S, et al. Retrospective study of 127 surgically treated patients with multiple brain metastases: indication, prognostic factors, and outcome. Acta Neurochir. 2013;155(3):379–387.
   PubMed Web of Science ®Google Scholar
• Picarelli H, Oliveira ML, Marta GN, et al. Mortality, morbidity, and prognostic factors in the surgical resection of brain metastases: a contemporary cohort study. J Neurol Surg A Cent Eur Neurosurg. 2020;81(4):279–289.
   PubMedGoogle Scholar
• Tryggvadóttir L, Gislum M, Hakulinen T, et al. Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):665–672.
   PubMed Web of Science ®Google Scholar